{"id":871168,"date":"2025-08-05T18:03:04","date_gmt":"2025-08-05T22:03:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/orasure-announces-second-quarter-2025-financial-results\/"},"modified":"2025-08-05T18:03:04","modified_gmt":"2025-08-05T22:03:04","slug":"orasure-announces-second-quarter-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/orasure-announces-second-quarter-2025-financial-results\/","title":{"rendered":"OraSure Announces Second Quarter 2025 Financial Results"},"content":{"rendered":"
\n

BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025.<\/p>\n

\u201cOur Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closely aligned with our customers as they navigate an environment with improving, but still elevated, levels of uncertainty related to funding for public health programs and research,\u201d said Carrie Eglinton Manner, President and CEO of OTI.<\/p>\n

She added, \u201cOur team is focused on advancing our innovation roadmap, as well as expanding our commercial reach and diversifying our client relationships in new segments under the leadership of our Chief Commercial Officer, Anne Messing, as we prepare to launch several new products. Overall, I am confident that OTI is well-positioned to deliver growth in 2026, and our strong balance sheet provides the flexibility to invest in organic and inorganic opportunities that leverage our existing capabilities to drive profitable long-term growth.\u201d<\/p>\n

\n Financial Highlights<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n For the Three Months Ended June 30,<\/strong>\n <\/td>\n\u00a0<\/td>\n\n For the Six Months Ended June 30,<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\n 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\n 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Core Business(1)<\/sup><\/td>\n$<\/td>\n30,768<\/td>\n\u00a0<\/td>\n$<\/td>\n32,283<\/td>\n\u00a0<\/td>\n(5<\/td>\n)%<\/td>\n\u00a0<\/td>\n$<\/td>\n58,822<\/td>\n\u00a0<\/td>\n$<\/td>\n60,401<\/td>\n\u00a0<\/td>\n(3<\/td>\n)%<\/td>\n<\/tr>\n
Molecular Services<\/td>\n\u00a0<\/td>\n\u2014<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n810<\/td>\n\u00a0<\/td>\n(100<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u2014<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,683<\/td>\n\u00a0<\/td>\n(100<\/td>\n)%<\/td>\n<\/tr>\n
Risk Assessment Testing<\/td>\n\u00a0<\/td>\n446<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2,308<\/td>\n\u00a0<\/td>\n(81<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,866<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n4,352<\/td>\n\u00a0<\/td>\n(57<\/td>\n)%<\/td>\n<\/tr>\n
COVID-19<\/td>\n\u00a0<\/td>\n28<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n18,934<\/td>\n\u00a0<\/td>\n(100<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n485<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n42,031<\/td>\n\u00a0<\/td>\n(99<\/td>\n)%<\/td>\n<\/tr>\n
\n Total Net Revenues<\/strong>\n <\/td>\n$<\/td>\n31,242<\/td>\n\u00a0<\/td>\n$<\/td>\n54,335<\/td>\n\u00a0<\/td>\n(43<\/td>\n)%<\/td>\n\u00a0<\/td>\n$<\/td>\n61,173<\/td>\n\u00a0<\/td>\n$<\/td>\n108,467<\/td>\n\u00a0<\/td>\n(44<\/td>\n)%<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n (1) Includes Diagnostics, Sample Management Solutions, other products and services revenues, and non-product and services revenues.<\/sup>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n For the Three Months Ended June 30,<\/strong>\n <\/td>\n\u00a0<\/td>\n\n For the Six Months Ended June 30,<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n<\/tr>\n
Net revenues<\/td>\n$<\/td>\n31,242<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n54,335<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(43<\/td>\n)%<\/td>\n\u00a0<\/td>\n$<\/td>\n61,173<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n108,467<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(44<\/td>\n)%<\/td>\n<\/tr>\n
Gross profit<\/td>\n\u00a0<\/td>\n13,159<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n24,689<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(47<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n25,458<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n48,754<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(48<\/td>\n)<\/td>\n<\/tr>\n
Gross margin<\/td>\n\u00a0<\/td>\n42.1<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n45.4<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n41.6<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n44.9<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP gross profit<\/td>\n\u00a0<\/td>\n13,512<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n25,771<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(48<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n25,980<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n50,218<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(48<\/td>\n)<\/td>\n<\/tr>\n
Non-GAAP gross margin<\/td>\n\u00a0<\/td>\n43.2<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n47.4<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n42.5<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n46.3<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating loss<\/td>\n\u00a0<\/td>\n(18,026<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(2,740<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(35,776<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(9,833<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating margin<\/td>\n(57.7<\/td>\n)%<\/td>\n\u00a0<\/td>\n(5.0<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(58.5<\/td>\n)%<\/td>\n\u00a0<\/td>\n(9.1<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP operating loss<\/td>\n\u00a0<\/td>\n(13,172<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3,346<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(28,452<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n3,022<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP operating margin<\/td>\n(42.2<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n6.2<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(46.5<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n2.8<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net loss<\/td>\n\u00a0<\/td>\n(19,693<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(615<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(35,733<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(4,199<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP net (loss) income<\/td>\n\u00a0<\/td>\n(14,193<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n5,774<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(27,332<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n8,860<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Diluted GAAP EPS<\/td>\n$<\/td>\n(0.26<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.01<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.48<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.06<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Diluted Non-GAAP EPS<\/td>\n$<\/td>\n(0.19<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n0.08<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.37<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n0.12<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n NM \u2013 not meaningful<\/sup>\n <\/p>\n